Welcome to our dedicated page for Biomark Diagnostics news (Ticker: BMKDF), a resource for investors and traders seeking the latest updates and insights on Biomark Diagnostics stock.
BioMark Diagnostics Inc. (BMKDF) regularly issues news and updates about its work in liquid biopsy-based early cancer detection, with a strong emphasis on lung cancer. The company’s announcements describe progress in applying metabolomics and machine learning to blood-based diagnostics, as well as developments in clinical validation, laboratory capacity, and international collaborations.
Readers of this news feed can follow BioMark’s participation in large-scale clinical studies, such as its role as a core diagnostic partner in the HANSE lung cancer screening trial in Germany and its involvement in multi‑thousand‑patient lung cancer studies in Canada. News items also cover recognition from organizations like ADRIQ and CQDM for multimodal lung cancer screening projects that integrate metabolomic blood tests, clinical data, and artificial intelligence.
Company releases provide detail on peer-reviewed publications, including work accepted in journals such as Frontiers in Oncology that report on machine learning-driven predictive models using pathway-based plasma metabolomic biomarkers. Updates also highlight the expansion of BioMark’s specialty laboratory services in Quebec, equipment upgrades that increase testing capacity, and steps toward laboratory certification and accreditation.
Investors and healthcare professionals can use this page to review announcements on intellectual property milestones, such as patents granted in China and Japan for BioMark’s metabolic liquid biopsy platform, as well as strategic agreements in regions like North Africa. By visiting this news section, users gain a consolidated view of BioMark’s clinical, operational, and strategic developments in oncology diagnostics.
BioMark Diagnostics (OTCQB: BMKDF) announced that a machine learning–driven metabolomics study for lung cancer detection has been accepted for publication in Frontiers in Oncology with notification dated January 15, 2026. The paper, titled "Translational impact of machine learning-driven predictive modeling with pathway-based plasma metabolomic biomarkers for lung cancer detection," describes pathway-level features from the Human Metabolome Database and interpretability using SHAP analysis.
The work was produced in collaboration with Dr. Maria Vaida at Harrisburg University and is expected to be published later this month and made available via the company website. BioMark frames the acceptance as third-party validation of its multi-year AI and machine learning investments in metabolomic profiling.
BioMark (OTCQB: BMKDF) reported major 2025 milestones that advance commercialization of its liquid biopsy platform for early cancer detection. Key 2025 achievements include a 7,000+ patient study completion, selection as exclusive partner for the HANSE 10,000 prospective lung cancer trial, submission of ISO 15189 certification documents in Dec 2025, doubled lab throughput, AI/ML investments, and $4.5M capital raised. Strategic funding includes Horizon Europe support and local grants. Planned 2026 catalysts: ISO accreditation to enable CLIA/CAP and U.S. market entry, HANSE data readouts, publications, licensing deals, launch of ISO-certified laboratory services, and scaling commercial and leadership hires.
BioMark Diagnostics (OTCQB: BMKDF) appointed James Lavender to its board after resolutions at the Annual General Meeting on December 22, 2025. Lavender was a major investor in BioMark's March 2025 financing and is described as supporting the company's transition from development to commercial execution.
BioMark said Lavender brings software development, enterprise sales, and AI/ML expertise, and has helped open high-level channels with state organizations and strategic investors to support the company’s planned U.S. market entry, certification finalization, and lab services expansion.
BioMark Diagnostics (OTCQB: BMKDF) has initiated an ISO 15189 accreditation program with the Standards Council of Canada for its medical laboratory in Quebec City, formally commencing on December 19, 2025.
The company expects an SCC site visit in early 2026 and says ISO 15189 will support its shift from R&D to a commercial-stage diagnostic provider by easing global market access and regulatory pathways. After achieving ISO 15189, BioMark intends to pursue CLIA and CAP accreditations to enable U.S. Laboratory Developed Test services. Management highlighted the accreditation as a quality milestone to reassure hospital procurement teams, biopharma partners, and payors.
BioMark Diagnostics (OTCQB: BMKDF) and research partners were awarded the ADRIQ Innovation Award on November 27, 2025 for a multimodal lung cancer screening project that combines a metabolomic blood test, clinical data and AI to estimate lung cancer probability. The project is valued at $4.42 million and was funded via the Government of Quebec through CQDM with support from AstraZeneca Canada, Pfizer Canada and IUCPQ-UL. The work created a biobank consolidating clinical data and samples from over 3,000 participants tied to Quebec’s lung screening program. BioMark says it is seeking accreditation for its Quebec facilities to support provincial integration and future international scaling.
BioMark Diagnostics (OTCQB: BMKDF) announced support for the 2026–2035 Pan-Canadian Lung Cancer Action Plan, aligning its next‑generation metabolomics and AI liquid biopsy approach with the plan's goal to reduce lung cancer mortality by 30% over the next decade. The company highlighted clinical results showing AI‑enabled biomarker testing can identify more early‑stage cancers, including in non‑smokers, and said its blood‑based tests can complement low‑dose CT screening and help expand access in underserved and remote communities.
BioMark invited partnerships with national and provincial healthcare providers and community organizations to scale early detection across Canada.
BioMark (OTCQB: BMKDF) was selected as the core diagnostic partner for Germany's HANSE lung cancer screening trial, a 10,000‑participant study that began in October 2025. The consortium will integrate metabolomic profiling, radiomics, and clinical data into a risk model to improve early lung cancer detection and nodule classification for adults aged 55–79. The initiative is supported by the EUREKA Network and involves multiple German clinical centers. BioMark cites a recent capital raise that enabled scaling of its Quebec City laboratory, which is progressing toward full certification to handle the trial's sample logistics. Successful execution is expected to provide clinical evidence for regulatory submissions and European commercialization.
BioMark Diagnostics (OTCQB: BMKDF) has secured crucial patents in China and Japan for its metabolic liquid biopsy platform designed for early lung cancer detection. The company's technology has demonstrated over 90% sensitivity for early-stage lung cancer detection in a recent study published in the International Journal of Molecular Sciences.
The granted patents (Chinese patent N° ZL 201980092723.X and Japanese patent N° 2023-111262) strengthen BioMark's position in Asia's largest healthcare markets, where the liquid biopsy market is projected to reach US$670 million in China and US$912 million in Japan by 2030.
BioMark Diagnostics (OTCQB: BMKDF) has entered a strategic Expression of Interest agreement with SAMA CONSULTING SARL to implement its liquid biopsy platform for lung cancer detection in Tunisia. The partnership aims to address the critical healthcare need in North Africa, where lung cancer is a leading cause of cancer-related deaths.
The collaboration will begin with a proof-of-concept trial in October 2025, evaluating the platform's performance within Tunisia's healthcare system. Following successful implementation, BioMark plans to expand across North Africa, potentially reaching a market of over 90 million people across Tunisia, Algeria, Morocco, and seven additional countries.
BioMark Diagnostics (OTCQB: BMKDF), a liquid biopsy test developer, has completed a strategic laboratory equipment leasing agreement that doubles its testing capacity in Quebec. This expansion supports the upcoming commercial launch of its metabolomic-based lung cancer diagnostic assay and enhances the company's ability to provide advanced diagnostic analytical molecular services.
The upgraded facility will serve as a certified and accredited laboratory, enabling broad deployment through clinical partnerships, centralized testing services, and expanded contract research programs. The expansion positions BioMark to meet increasing global demand for non-invasive liquid biopsy diagnostics and supports research collaborations with healthcare institutions and pharmaceutical companies.
FAQ
What is the current stock price of Biomark Diagnostics (BMKDF)?
What is the market cap of Biomark Diagnostics (BMKDF)?
